UNSPSC 51283210: Troleandomycin

This classification denotes a macrolide antibiotic with the molecular formula C41H67NO15, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier C4DZ64560D, chemically known as oleandomycin, triacetyl- but generally known as triacetyloleandomycin, which bears US NIH Compound Identifier 17675. European Medicines Agency schedules Troleandomycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11333MIG.

UNSPSC 51283210 Troleandomycin is a Commodity code that nominally identifies a specific macrolide antibiotic, yet recent state and local procurement activity under this code reflects broader pharmaceutical and medical supply acquisition. The actual work being solicited spans generic multi-source pharmaceuticals, over-the-counter products, naloxone and drug deactivation systems, and medical and first aid supplies for emergency responder and public health use. State and local issuing bodies include county health departments, state health and human services commissions, municipal fire departments, and multistate cooperative purchasing alliances. Seminole County, Florida; the Texas Health and Human Services Commission; the City of Tampa; and the Minnesota Department of Administration have all posted opportunities under or closely aligned with this code in the past six months, indicating that purchasing offices are using the code to solicit a range of pharmaceutical and medical consumables rather than troleandomycin specifically.

Geographic activity spans Florida, Texas, Minnesota, and Oregon, with multistate cooperative procurement vehicles creating broader reach. The most recent representative opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for naloxone and drug deactivation systems with annual quantities of 1,900 units and 800 units respectively; the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities; the City of Tampa's Bid 26-P-00145 (due March 13, 2026, estimated contract value $700,000) for medical and first aid supplies designated as a sheltered market opportunity for certified Small Local Business Enterprises with a 5 percent bid discount; and the Texas HHS Commission's RFI HHS0017013 (due April 3, 2026) to gather vendor capabilities for direct-to-manufacturer prescription programs. The code shows active state and local procurement but diverges significantly from its nominal scope, suggesting that business development professionals should monitor activity under broader pharmaceutical and medical supply codes rather than relying on this specific commodity designation.